149 related articles for article (PubMed ID: 21075705)
1. Does radiographic evidence of prior pulmonary tubercular infection influence the choice of empiric antibiotics for community-acquired pneumonia in a tuberculosis-endemic area?
Jeng YY; Lin YT; Huang LJ; Chen TL; Wang FD; Fung CP; Liu CY
J Microbiol Immunol Infect; 2010 Oct; 43(5):386-94. PubMed ID: 21075705
[TBL] [Abstract][Full Text] [Related]
2. The impact of empiric antimicrobial therapy with a β-lactam and fluoroquinolone on mortality for patients hospitalized with severe pneumonia.
Mortensen EM; Restrepo MI; Anzueto A; Pugh J
Crit Care; 2005 Dec; 10(1):R8. PubMed ID: 16420641
[TBL] [Abstract][Full Text] [Related]
3. Comparison of Empiric Antibiotic Treatment Regimens for Hospitalized, Non-severe Community-acquired Pneumonia: A Retrospective, Multicenter Cohort Study.
Reeves SD; Hartmann AP; Tedder AC; Juang PA; Hofer M; Kollef MH; Micek ST; Betthauser KD
Clin Ther; 2024 Apr; 46(4):338-344. PubMed ID: 38403509
[TBL] [Abstract][Full Text] [Related]
4. Comparison of beta-lactam and macrolide combination therapy versus fluoroquinolone monotherapy in hospitalized Veterans Affairs patients with community-acquired pneumonia.
Lodise TP; Kwa A; Cosler L; Gupta R; Smith RP
Antimicrob Agents Chemother; 2007 Nov; 51(11):3977-82. PubMed ID: 17709460
[TBL] [Abstract][Full Text] [Related]
5. Antibiotic treatment outcomes in community-acquired pneumonia.
Çilli A; Sayıner A; Çelenk B; Şakar Coşkun A; Kılınç O; Hazar A; Aktaş Samur A; Taşbakan S; Waterer GW; Havlucu Y; Kılıç Ö; Tokgöz F; Bilge U
Turk J Med Sci; 2018 Aug; 48(4):730-736. PubMed ID: 30119147
[TBL] [Abstract][Full Text] [Related]
6. Effect of β-Lactam Plus Macrolide Versus Fluoroquinolone on 30-Day Readmissions for Community-Acquired Pneumonia.
Gilbert TT; Arfstrom RJ; Mihalovic SW; Dababneh AS; Varatharaj Palraj BR; Dierkhising RA; Mara KC; Lessard SR
Am J Ther; 2020; 27(2):e177-e182. PubMed ID: 30418221
[TBL] [Abstract][Full Text] [Related]
7. Antibiotic treatment strategies for community-acquired pneumonia in adults.
Postma DF; van Werkhoven CH; van Elden LJ; Thijsen SF; Hoepelman AI; Kluytmans JA; Boersma WG; Compaijen CJ; van der Wall E; Prins JM; Oosterheert JJ; Bonten MJ;
N Engl J Med; 2015 Apr; 372(14):1312-23. PubMed ID: 25830421
[TBL] [Abstract][Full Text] [Related]
8. β-Lactam monotherapy vs β-lactam-macrolide combination treatment in moderately severe community-acquired pneumonia: a randomized noninferiority trial.
Garin N; Genné D; Carballo S; Chuard C; Eich G; Hugli O; Lamy O; Nendaz M; Petignat PA; Perneger T; Rutschmann O; Seravalli L; Harbarth S; Perrier A
JAMA Intern Med; 2014 Dec; 174(12):1894-901. PubMed ID: 25286173
[TBL] [Abstract][Full Text] [Related]
9. Is β-Lactam Plus Macrolide More Effective than β-Lactam Plus Fluoroquinolone among Patients with Severe Community-Acquired Pneumonia?: a Systemic Review and Meta-Analysis.
Lee JH; Kim HJ; Kim YH
J Korean Med Sci; 2017 Jan; 32(1):77-84. PubMed ID: 27914135
[TBL] [Abstract][Full Text] [Related]
10. Does empirical treatment of community-acquired pneumonia with fluoroquinolones delay tuberculosis treatment and result in fluoroquinolone resistance in Mycobacterium tuberculosis? Controversies and solutions.
Shen GH; Tsao TC; Kao SJ; Lee JJ; Chen YH; Hsieh WC; Hsu GJ; Hsu YT; Huang CT; Lau YJ; Tsao SM; Hsueh PR
Int J Antimicrob Agents; 2012 Mar; 39(3):201-5. PubMed ID: 22285045
[TBL] [Abstract][Full Text] [Related]
11. Fluoroquinolone treatment of community-acquired pneumonia: a meta-analysis.
Salkind AR; Cuddy PG; Foxworth JW
Ann Pharmacother; 2002 Dec; 36(12):1938-43. PubMed ID: 12452758
[TBL] [Abstract][Full Text] [Related]
12. Outcomes of health care-associated pneumonia empirically treated with guideline-concordant regimens versus community-acquired pneumonia guideline-concordant regimens for patients admitted to acute care wards from home.
Chen JI; Slater LN; Kurdgelashvili G; Husain KO; Gentry CA
Ann Pharmacother; 2013 Jan; 47(1):9-19. PubMed ID: 23324506
[TBL] [Abstract][Full Text] [Related]
13. Atypical coverage in community-acquired pneumonia after outpatient beta-lactam monotherapy.
van Werkhoven CH; van de Garde EMW; Oosterheert JJ; Postma DF; Bonten MJM
Respir Med; 2017 Aug; 129():145-151. PubMed ID: 28732822
[TBL] [Abstract][Full Text] [Related]
14. Comparative effectiveness of empiric β-lactam monotherapy and β-lactam-macrolide combination therapy in children hospitalized with community-acquired pneumonia.
Ambroggio L; Taylor JA; Tabb LP; Newschaffer CJ; Evans AA; Shah SS
J Pediatr; 2012 Dec; 161(6):1097-103. PubMed ID: 22901738
[TBL] [Abstract][Full Text] [Related]
15. Severe community-acquired pneumonia treated with β-lactam-respiratory quinolone vs. β-lactam-macrolide combination.
Karhu J; Ala-Kokko TI; Ohtonen P; Syrjälä H
Acta Anaesthesiol Scand; 2013 May; 57(5):587-93. PubMed ID: 23379766
[TBL] [Abstract][Full Text] [Related]
16. Community-acquired pneumonia and tuberculosis: differential diagnosis and the use of fluoroquinolones.
Grossman RF; Hsueh PR; Gillespie SH; Blasi F
Int J Infect Dis; 2014 Jan; 18():14-21. PubMed ID: 24211230
[TBL] [Abstract][Full Text] [Related]
17. Guideline-concordant antibiotic use and survival among patients with community-acquired pneumonia admitted to the intensive care unit.
Frei CR; Attridge RT; Mortensen EM; Restrepo MI; Yu Y; Oramasionwu CU; Ruiz JL; Burgess DS
Clin Ther; 2010 Feb; 32(2):293-9. PubMed ID: 20206787
[TBL] [Abstract][Full Text] [Related]
18. Empirical use of fluoroquinolones improves the survival of critically ill patients with tuberculosis mimicking severe pneumonia.
Tseng YT; Chuang YC; Shu CC; Hung CC; Hsu CF; Wang JY
Crit Care; 2012 Oct; 16(5):R207. PubMed ID: 23098258
[TBL] [Abstract][Full Text] [Related]
19. Empiric treatment in hospitalized community-acquired pneumonia. Impact on mortality, length of stay and re-admission.
Reyes Calzada S; Martínez Tomas R; Cremades Romero MJ; Martínez Moragón E; Soler Cataluña JJ; Menéndez Villanueva R
Respir Med; 2007 Sep; 101(9):1909-15. PubMed ID: 17628462
[TBL] [Abstract][Full Text] [Related]
20. Empiric Anti-Pseudomonal β-Lactam Monotherapy Versus Fluoroquinolone Combination Therapy in Patients With Hospital-Acquired Pneumonia: A Multicenter Cohort Study With Propensity Score Matching.
Baek MS; Baek AR; Hong SB; Bae S; Park HK; Kim C; Lee HK; Cho WH; Kim JH; Chang Y; Lee HB; Gil HI; Shin B; Yoo KH; Moon JY; Oh JY; Min KH; Jeon K;
J Korean Med Sci; 2023 Oct; 38(41):e353. PubMed ID: 37873633
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
